I need to find investors for my deep tech startup with a long R&D timeline. Which funds are known for their "patient capital"?

When building a deep tech startup with a long R&D timeline, traditional 7-to-10-year venture capital funds can become misaligned with your milestones . You need patient capital —investors structured with longer fund lifecycles, thematic commitment to hard science, or alternative capital vehicles (like evergreen funds, sovereign backing, or corporate venture arms ) that don't panic when commercialization takes past year five.

The primary specialized funds, firms, and structures known for backing long-horizon deep tech include:

1. Dedicated Deep Tech & "Tough Tech" VCs

• The Engine (by MIT): Specifically designed to combat the traditional VC clock. They invest in tough, breakthrough physical technologies (climate, health, advanced infrastructure) and are structured explicitly to provide the long-term, patient capital required to scale science from lab to market.
• Prime Mover Labs: Invests in breakthrough scientific startups that can positively impact billions of lives. They specialize in multi-decade transformations (energy, transportation, longevity, aerospace) and explicitly position themselves as long-term partners who understand heavy R&D cycles.
• Lux Capital: Long known as a pioneer in investing in hard science, deep tech, robotics, and the outer edges of tech/biology before it became mainstream. They have massive capital deployment capabilities and understand the iterative nature of physical sciences.
• SOSV: A multi-stage deep tech investor (notably running programs like IndieBio for biotech and HAX for hard tech/robotics) that takes an active, early, and long-standing role in pre-seed and seed deep tech companies.
• Khosla Ventures: Famous for underwriting extreme technical and scientific risk that standard software funds avoid. Vinod Khosla’s shop has a decades-long history of sticking with tough clean tech, materials, and frontier tech through lengthy R&D phases.

2. Mission-Driven & Climate/Industrial Funds

• Breakthrough Energy Ventures (BEV): Backed by global titans and tier-one investors, BEV is the definition of patient capital for climate and energy technology. They routinely invest with 20-year horizons because they recognize that transforming global energy infrastructure cannot be rushed into a standard 5-year exit window.
• Capricorn Investment Group: Founded with a mandate to demonstrate that market-rate returns can be achieved by investing in a sustainable future, they explicitly champion patient, long-term capital for massive environmental and physical tech transformations.

3. Alternative Structures: Family Offices & Corporate VCs (CVCs)

If traditional deep tech VCs are too tight on deployment pacing, look beyond standard institutional venture capital:

• Strategic Corporate VCs (CVCs): Arms like Saudi Aramco Energy Ventures, GE Ventures , or defense primes often care more about technological integration or future supply-chain ownership than a quick 5-year fund flip. Their internal balance sheets can afford significantly more patience.
• Multi-Generational Family Offices: Single-family offices (especially those rooted in heavy industry, manufacturing, or natural resources) frequently manage generational wealth. They do not operate on a 10-year LP cycle and are often ideal targets for heavy infrastructure or deep materials science startups.

If you'd like to narrow this down, let me know:

• What specific sector is your deep tech startup in (e.g., climate tech, fusion, advanced materials, biotech, quantum)?
• What stage of funding (Pre-seed, Seed, Series A) are you currently raising for?

Absolutely. For a deep-tech company with a 5–10+ year R&D-to-commercialization path, I’d prioritize investors whose fund structure, portfolio history, and stated strategy actually accommodate long technical timelines—not just VCs that use “deep tech” as a label.

Strong U.S. candidates

• dcvc.com — One of the strongest generalist deep-tech fits. DCVC explicitly emphasizes long-term founder relationships and has invested across climate, engineering, materials, robotics, space, biology, and defense. Its own language is telling: “We are in a hurry to do things that take time.”
• primemoverslab.com — Particularly interesting for breakthrough science in energy, transportation, infrastructure, manufacturing, agriculture and human augmentation. They invest at the invention/science stage and deliberately make relatively few investments so they can work deeply with founders.
• The Engine (MIT) — A particularly good target if you're commercializing hard science that needs substantial technical development, specialized equipment or long validation cycles. It is repeatedly identified as a patient-capital deep-tech investor.
• Lux Capital — Worth targeting for frontier science/engineering, particularly AI, biotech, advanced computing and other technically ambitious areas. It appears among the major deep-tech investors identified in industry analyses.
• SOSV / HAX — Especially relevant if you have a hardware-heavy startup and need capital plus help getting from prototype to manufacturable product. SOSV is a recurring name in deep-tech investor surveys.

Europe / UK

• arcas.vc — An unusually direct match: its stated positioning is literally “Patient capital for impatient founders.” It invests at pre-seed/seed in European deep tech and can follow on.
• British Patient Capital — Particularly relevant for later-stage UK deep tech; it is specifically identified as a Series C+ deep-tech investor in Dealroom's European deep-tech data.
• Martlet Capital — Focuses on early-stage deep technology and life sciences and is explicitly described as providing patient capital.
• IQ Capital — Good fit for technically difficult UK companies; it invests from seed through growth and has a long-standing deep-tech orientation.
• Parkwalk Advisors — Particularly worth considering if you're coming out of a university or research institution; it is a major UK university spinout investor.
• 55 North — A newer specialist worth knowing if you're in quantum. It explicitly describes its strategy as providing long-horizon, patient capital to take quantum technology from lab to market.

If you're biotech / life sciences

I'd add DCVC Bio, Lightstone Ventures, and Crista Galli Ventures to the list.

Lightstone explicitly says its patient capital is intended to fund companies through the lifecycle from startup to commercialization. Crista Galli is particularly interesting because it uses an evergreen structure rather than the conventional finite VC-fund cycle, specifically to give health-tech companies more runway through regulatory and efficacy hurdles.

One important distinction

“Patient capital” can mean several different things:

1. Long fund duration — the investor can hold equity for 10+ years.
2. Follow-on capacity — they can keep funding you through multiple R&D rounds.
3. Technical tolerance — they're comfortable investing before the science is fully de-risked.
4. Milestone-based financing — they understand that value creation happens at scientific/technical milestones rather than SaaS-style revenue growth.
5. Non-VC capital — government grants, strategic investors, family offices, sovereign funds and corporate venture can sometimes be more patient than conventional VC.

For a genuinely long-R&D startup, I'd therefore build your investor pipeline around DCVC + Prime Movers Lab + The Engine + one or two sector-specific specialists, then supplement that with strategic/corporate and non-dilutive capital.

If you tell me what the technology is, current TRL/stage, how much you're raising, and roughly how many years until commercialization, I can narrow this to 10–15 funds that are genuinely plausible targets, including their typical stage/check size, geography, relevant portfolio companies, and who at each fund is most likely to care.

Yes. For a deep-tech company where R&D, regulatory approval, manufacturing scale-up, or scientific validation can take 7–15+ years, you want investors whose fund structure and portfolio philosophy can tolerate that timeline—not just investors who happen to like deep tech.

Here’s the shortlist I’d start with:

A few newer/specialized ones worth investigating

• Next Wave Partners is unusually explicit about the problem you're describing. It says traditional VC isn't designed for deep tech and offers patient capital, embedded operators, and founder-aligned structures, particularly for autonomy, robotics and intelligent infrastructure.
• Qindra is focused on quantum and deep tech and explicitly describes its strategy as combining deep-tech investing with patient capital and venture building.
• Ignite Intelligence Venture describes itself as a frontier AI/deep-tech fund with “patient capital, no fund lifecycle,” which is potentially interesting if you're in AI, semiconductors, robotics, biotech, aerospace, etc.
• Delin Ventures explicitly says it has the patience and focus to support companies for long-term success and invests across life sciences and technology.

The important distinction: “deep tech” ≠ “patient”

I'd actually divide prospective investors into three buckets:

1. True patient-capital investors They are comfortable with long periods before meaningful revenue or an exit. These are your highest-priority targets.

2. Deep-tech VCs with patient behavior They understand the technology but may still have conventional 10-year fund economics. DCVC, Lux and Prime Movers can fall into this category depending on the particular fund/partner.

3. Capital that extends the runway Government grants, strategic corporate investors, family offices, project finance and specialized funds can be extremely valuable because they reduce the amount of conventional VC you need.

That third category is particularly important. For a company requiring, say, $50M before commercialization, raising all $50M as ordinary priced VC can create a painful cap table. Grants, strategic partnerships and milestone-based financing can get you to the next technical inflection point without giving away as much equity.

How I'd approach the fundraising

Instead of pitching “we need patient investors because this will take 10 years,” I'd pitch:

“Our next value inflection point is X, which requires Y months and $Z. Once we achieve it, the technical/commercial risk drops from A to B.” Patient investors still want milestones. What they tolerate is longer time between milestones, not an absence of milestones.

If you tell me what your technology is, current stage (e.g. lab/prototype/pilot), amount you're raising, geography, and expected time to commercialization, I can narrow this to 10–20 specific funds that are genuinely appropriate, including likely check sizes, stage, relevant portfolio companies, and which partner you should approach.

Finding "patient capital" for a deep tech startup with a long R&D horizon means looking past traditional 10-year venture capital funds that expect a fast liquidity event. You need investors who understand Technology Readiness Levels (TRLs), hardware/science iteration, and extended timelines.

The prominent venture capital firms and investment models known for backing long-horizon, hard-science, and deep tech ventures include:

Dedicated Deep Tech & Frontier Funds

• Lux Capital: Managing multi-billion dollar portfolios (including Lux Ventures IX ), they specialize explicitly in the outer edges of science and tech—from advanced materials and space to synthetic biology and AI . They back companies across the full arc from inception to late-stage growth.
• Prime Movers Lab: Invests in breakthrough scientific startups aiming to transform massive markets (energy, longevity, transportation, manufacturing). They explicitly champion "patient capital" and back founders whose inventions require prolonged scientific de-risking.
• Lowercarbon Capital: For climate, energy, and physical decarbonization deep tech, Chris Sacca’s fund provides extended timelines (often stretching past standard horizons) and even maintains in-house R&D testing facilities for portfolio companies.
• Fifty Years: A seed-stage fund that partners explicitly with scientists solving big global problems (synthetic biology, human health, planetary health). They operate with a philosophy geared toward multi-year fundamental research translation rather than fast software flips.
• SOSV: Known heavily for its hard-tech and bio accelerators (like IndieBio and HAX), SOSV writes early checks and provides specialized lab space, supporting founders through the brutal hardware/wet-lab prototyping phases.

Generalist / Multi-Stage Giants with Deep Tech Arms

• Khosla Ventures: Historically one of the most aggressive and conviction-heavy backers of "radical" and contrarian science (fusion, agtech, grid-scale energy, robotics) that others write off as too slow or risky.
• Founders Fund: Famous for backing long-term bets on aerospace (SpaceX), defense tech (Anduril), and hard tech where timelines span well over a decade.
• General Catalyst & Bain Capital Ventures: Both have dedicated teams and increasing allocations toward industrial transformation, defense, and resilient infrastructure requiring multi-year development paths.

Alternative Structures: Corporate VCs (CVCs) & Sovereigns

If your R&D timeline exceeds typical fund lifecycles, look closely at non-traditional venture conduits:

• Strategic Corporate VCs: Entities like BMW i Ventures, GE Ventures , or Toyota Ventures have balance sheets that aren't bound by a strict 10-year LP fund clock if the underlying tech aligns with their 20-to-30-year corporate roadmap.
• Defense & National Security Funds: Organizations like DIU (Defense Innovation Unit) or the UK's NS&I / National Security Strategic Investment Fund offer non-dilutive capital or patient funding aligned with strategic state interests.

To help narrow down which of these matches your exact profile, tell me:

• What vertical is your startup in (e.g., fusion, quantum, synthetic biology, aerospace)?
• What funding stage are you currently raising for (Pre-Seed, Seed, or Series A)?

Finding investors with true patient capital is essential for deep tech startups facing multi-year R&D timelines, hardware iteration, or regulatory hurdles. Traditional 10-year venture funds often grow anxious if commercial revenue isn't visible within 24 months, but specialized hard-science and tough-tech funds are structured differently.

The prominent funds and investment entities known for backing deep tech with extended horizons include:

• The Engine (by MIT) - Located in Cambridge, MA, this firm was specifically built by MIT to invest in "tough tech" (climate, advanced systems, health). They offer prolonged investment horizons alongside specialized lab infrastructure and workspace.
• Breakthrough Energy Ventures - Backed by global private investors, BEV prioritizes planetary impact and fundamental technological change over rapid financial returns, making them uniquely patient for capital-intensive climate and energy deep tech.
• DCVC (Data Collective) - Focuses heavily on computational science, hard tech, synthetic biology, and robotics, possessing the deep technical literacy needed to evaluate and support pre-revenue science risks.
• Lux Capital - Known for investing at the intersection of science and radical ideas—spanning space, defense, advanced materials, and health tech—with a high tolerance for early technical risk.
• Prime Movers Lab - Invests in early-stage breakthrough inventions (reinventing energy, transportation, infrastructure, and human augmentation) with a mandate explicitly tailored to stubborn, multi-year scientific innovation cycles.
• Playground Global - Founded by engineering pioneers, they back early-stage, ambitious deep tech and hardware-heavy companies that require an intense and prolonged R&D phase before hitting scale.
• SOSV - Particularly via programs like HAX (for hardware and robotics) and IndieBio (for synthetic biology and biotech), SOSV acts as a long-term partner starting from the earliest inception stages, guiding companies through messy laboratory and prototyping phases.
• Flagship Pioneering - Dominant in life sciences and biotech, they operate on an institutional "venture creation" model, systematically building and funding platform companies from scratch over many years.

If you tell me your specific sector (e.g., climate tech, quantum computing, biotech, advanced materials) and your current funding stage (pre-seed, seed), I can help you narrow down which of these specific funds is the best fit for your milestone roadmap.

For a deep tech startup with a long R&D timeline, you generally want investors whose fund structure matches 10+ year commercialization cycles, not just VCs who say they like “moonshots.” Patient capital investors often have one or more of these characteristics: evergreen structures, government/strategic LPs, university links, large follow-on reserves, or a history of funding science before revenue. Deep tech often needs longer horizons than traditional venture models because hardware, biotech, energy, and advanced materials can take many years to mature.

Here are funds and investor groups commonly associated with patient capital:

Deep tech / frontier technology

• DCVC — Focuses specifically on deep tech, backing companies tackling difficult scientific and engineering problems. It has invested in areas such as climate, biology, AI, and advanced industrial technologies.

• Breakthrough Energy Ventures — Known for a long investment horizon (often cited around 20 years) because climate technologies may require lengthy R&D, commercialization, and infrastructure buildout cycles.

• SOSV — A major early-stage deep tech investor, particularly through its HAX and IndieBio programs, supporting hardware, climate, biotech, and frontier science companies.

• Khosla Ventures — Historically associated with ambitious science-driven bets in areas like energy, biology, and AI where outcomes may take years.

• Founders Fund — Known for investing in technically ambitious companies that challenge conventional venture timelines.

Hard science / biotech / life sciences

• ARCH Venture Partners — One of the best-known investors in science-based companies, frequently backing startups originating from universities and research labs.

• Third Rock Ventures — Built around creating and financing biotech companies from scientific discoveries, often before commercial validation.

• Lightstone Ventures — Invests in medical breakthroughs and describes its approach as using long-term, patient capital through company-building cycles.

• RA Capital Management — Focuses on scientifically ambitious healthcare companies and explicitly describes itself as patient capital oriented toward enduring companies rather than quick exits.

Government-backed / institutional patient capital

• British Patient Capital — Created specifically to address the patient-capital gap for innovative companies and invests through venture and growth funds with longer horizons.

• KfW Capital — A major European deep-tech ecosystem investor, often backing funds and companies where commercialization takes longer.

Corporate strategic investors (often patient when aligned)

For some deep tech categories, corporate venture arms can be more patient because they care about strategic value, not only financial exit timing:

• Microsoft — AI, quantum, cloud infrastructure, and enterprise deep tech.
• Intel — Chips, manufacturing, AI infrastructure.
• Merck & Co. / MRL Ventures Fund — Therapeutics-focused investing with long development cycles.

What to look for when evaluating a “patient” investor

Ask these questions before taking money:

1. Fund life: Does the fund have a 10-year+ horizon, extensions, or evergreen structure?
2. Follow-on capacity: Can they fund Series B/C/D rounds when commercialization takes longer?
3. Technical tolerance: Have they funded companies before revenue, prototypes, or regulatory approval?
4. Exit pressure: Are they comfortable with strategic acquisitions or delayed IPO paths?
5. Milestone alignment: Do they understand scientific milestones (TRL, clinical phases, manufacturing scale-up), not just ARR?

For a deep tech company, the best investor is often not the one offering the highest valuation at seed; it is the one whose capital still fits when the company is five years in, has burned significant R&D dollars, and is approaching the hardest commercialization phase.

If you share your sector (e.g., quantum, robotics, biotech, climate, materials, defense, semiconductors) and stage (pre-seed/seed/Series A), I can narrow this to a more targeted investor list.

Finding "patient capital" for a deep tech startup with a multi-year R&D timeline means looking for specialized venture funds . Traditional software-focused VCs operate on a tight 7-to-10-year fund cycle requiring rapid commercial revenue, but dedicated deep/tough tech funds are structured specifically with the technical literacy and extended horizons needed for science-risk ventures.

Top institutional funds known for deploying patient capital into long-timeline R&D include:

• Engine Ventures (formerly The Engine) – Spinout from MIT built specifically to fund "tough tech" (climate, advanced systems, human health). They offer specialized labs, infrastructure, and an explicitly extended capital timeline.
• Lux Capital – Long-standing heavy hitter in frontier sciences, advanced materials, space, and deep biotech, with multi-decade experience backing physics- and chemistry-heavy breakthroughs.
• DCVC (Data Collective) – Deeply technical fund focusing on hard science, computational engineering, robotics, and synthetic biology, comfortable with deep enterprise R&D before revenue exists.
• Prime Movers Lab – Invests specifically in breakthrough scientific inventions and energy, infrastructure, and manufacturing transformations that take substantially longer to commercialize than software.
• SOSV – Famous for running specialized hard-tech and life science incubation platforms (like HAX and IndieBio) that support founders from the lab-bench stage forward.
• Breakthrough Energy Ventures – Backs innovations explicitly aimed at reducing greenhouse gas emissions, designed from the ground up for massive, capital-intensive, multi-decade energy transitions.
• Khosla Ventures – Historically willing to take early, contrarian, science-heavy bets across synthetic biology, clean tech, and advanced hardware at the R&D stage.
• Flagship Pioneering – Operates on a unique venture-creation model for life sciences and platform technologies, inventing and nurturing companies internally through years of foundational R&D.

To help narrow down which of these (or other regional/sector-specific) funds might be the best fit, tell me:

• What is your specific sector (e.g., fusion, quantum, synbio, advanced materials)?
• What is your estimated R&D timeline before reaching commercialization or a major hardware milestone?

For a deep tech startup with a long R&D timeline, you generally want investors whose fund structure, LP expectations, and investment philosophy allow them to wait through technical milestones rather than pushing for a fast exit. Deep tech often takes substantially longer to mature than software startups, with some technologies requiring many years of scientific validation and commercialization.

Funds and investor groups often associated with patient capital include:

Other categories worth exploring:

• University-affiliated deep tech funds — especially if your company is a spinout from a lab or research institution.
• Government-backed patient capital vehicles — often designed to bridge the “valley of death” between research breakthroughs and commercialization.
• Corporate venture arms with strategic R&D interests — useful when your technology aligns with a large company’s future roadmap.
• Family offices and evergreen funds — some can tolerate longer holding periods because they are not bound by traditional VC fund cycles.

When approaching these investors, emphasize:

• the technical moat (why this cannot easily be replicated),
• the scientific milestones that reduce risk over time,
• the capital required to reach commercialization, and
• why a 7–15 year timeline creates a large outcome rather than simply a long wait.

If you share your deep tech area (e.g., quantum, robotics, biotech, materials, climate, semiconductors, AI infrastructure) and geography, I can narrow this to investors who actually write checks in that category.

Finding "patient capital"—investors with the technical literacy, specialized fund structures, and extended timelines required to back science-risk and heavy-R&D startups—is critical . Traditional 10-year venture capital funds often feel pressured to exit long before a hard-science or atomic-scale technology hits the market.

The following prominent venture capital firms and funds are purpose-built or well-known for providing patient capital to deep tech, hard tech, and frontier science startups:

• Engine Ventures (The Engine) — Spun out of MIT, this firm is explicitly structured to support "tough tech" with long R&D timelines. They provide patient capital alongside access to specialized lab infrastructure and equipment.
• Breakthrough Energy Ventures (BEV) — Backed by a coalition of global leaders, BEV targets science-driven decarbonization across electricity, manufacturing, and agriculture. They operate with a much longer investment horizon than traditional VCs, explicitly tailored for capital-intensive climate breakthroughs.
• DCVC (Data Collective) — Specializes in hard science, computational biology, robotics, and advanced infrastructure. They understand how to evaluate deep technical risks and stick with companies through multi-year development cycles.
• Lux Capital — Known for investing at the intersection of science and radical ideas (advanced materials, space, defense, and deep health tech). They have massive scale and the conviction to back high-risk, long-gestation physical technologies.
• Prime Movers Lab — Invests in early-stage "prime movers," or revolutionary scientific startups that invent breakthrough technologies in energy, transportation, infrastructure, and manufacturing, with a multi-decade mindset.
• Flagship Pioneering — A massive force in life sciences and synthetic biology. Rather than just investing passively, they internally "invent" and incubate companies from scratch, giving them unmatched institutional patience and capital commitment from day zero.
• SOSV (via HAX and IndieBio) — While they engage at the pre-seed/seed stage, their program-driven ecosystem (HAX for hard tech/robotics and IndieBio for life sciences) provides specialized labs, non-dilutive support, and follow-on capital strategies designed specifically for hardware and biotech lifecycles.
• Khosla Ventures — Frequently utilizes parallel or concurrent fund structures that allow them to maintain a high-conviction, long-term pool of patient capital across the entire lifetime of a company.

To help me point you toward the most relevant subset of investors , could you share:

• Your specific vertical (e.g., fusion/energy, quantum, synbio, advanced materials, aerospace)?
• Your current stage and capital needs (pre-seed/seed vs. scaling an R&D pilot)?

Yes. For a deep-tech company where technical de-risking, commercialization, and meaningful revenue may take 7–15+ years, I’d prioritize investors whose fund structure and track record actually support long holding periods—not merely VCs who use the phrase “patient capital.”

Strong U.S. candidates

DCVC is particularly notable because its current platform includes dedicated climate and bio funds in addition to its broader deep-tech strategy.

An interesting newer option

Kenshō Ventures is unusually explicit about this. It describes its model as “patient capital,” makes relatively few €500K pre-seed/seed investments per year, and says it is designed around a long horizon for technologies that take time to mature. Its focus is European resilience tech: robotics, quantum, industrial AI and cybersecurity/dual use.

Don't overlook non-VC capital

For genuinely long R&D cycles, the best financing strategy is often VC + non-dilutive capital + strategic investors, rather than trying to find one magical patient VC.

For example:

• Government R&D grants/contracts
• University technology-transfer funding
• Corporate strategic investors
• Government-backed deep-tech funds
• Venture philanthropy, particularly for certain biotech/medical applications
• Project finance or equipment financing once technical risk falls

That's important because a conventional VC fund can still have a nominal 10-year fund life even if the partner personally likes your technology. The question to ask isn't just “Are you patient?” but “How long have you historically held companies, and what happens if we need another 3–5 years of R&D before commercialization?”

There is empirical support for taking this seriously: recent research finds that longer-horizon LP capital can cause VC funds to shift toward earlier-stage investing and longer holding periods.

How I'd build your investor shortlist

I'd score each fund on five dimensions:

1. Longest historical holding period
2. Number of investments in companies with >5 years of technical development
3. Ability to follow on through Series B/C and beyond
4. Actual scientific/engineering expertise on the investment team
5. Comfort with milestone-based value creation rather than near-term revenue

If you tell me what your deep-tech startup actually does, your stage, how much you're raising, and roughly how many years until commercialization, I can narrow this to 10–20 specific funds that are genuinely plausible targets, including typical check size, relevant portfolio companies, partner names, and why each one fits.